Avon Protection warns over body armour revenue contribution

Avon Protection tanked on Friday after it warned the revenue contribution from its body armour segment for FY22 and beyond will be "significantly reduced" following a testing failure for one of its products and delays to product approvals.

The maker of gas masks and helmets said the US Army Vital Torso Protection (VTP) ESAPI body armour plates have encountered a testing failure that will significantly delay the likely approval timetable for the product.

Separately, it has experienced further delays in obtaining final product approvals for the DLA ESAPI body armour plates, with approvals for this product now expected in the second quarter of the year ending 30 September 2022.

As a result, Avon has initiated a strategic review of the body armour business.

The group's FY22 revenue guidance had included around $40m of body armour revenue. However, due to the issues mentioned above, this contribution is now expected to be "significantly reduced", with the ultimate impact, including any associated cost savings, depending on the outcome of the review process.

Avon said its respiratory protection and helmet product portfolios are unaffected.

The group said its underlying trading results for FY21 are expected to be in line with the guidance given in the update on 13 October. However, it has delayed the announcement of its FY21 results, which had been due on 23 November, "to allow for a review of the carrying value of the assets related to the body armour business and the additional audit work arising from this post balance sheet event".

At 1335 GMT, the shares were down 44% at 1,076.00p.

Russ Mould, investment director at AJ Bell, said: "It’s almost as if the last two-and-a-half years or so for defence business Avon Protection was some kind of fever dream, with the shares having raced up all the way to record highs above £46 last October before seeing an equally stratospheric fall to today trade at levels they were at in the summer of 2019.

"As a result, a share price chart of Avon for the last few years looks like the sort of forbidding mountainous peak which would strike fear into the hearts of even the bravest climber and the stock has proved just as treacherous for shareholders.

"Clearly the market got carried away with the potential of its personal protection equipment - sold to the military and emergency services. This was particularly true when the company sold off its dairy products division, allowing investors to focus exclusively on the protection potential.

"Trading on an elevated valuation left the business vulnerable to the slightest disappointment. And in Avon’s case the disappointments weren’t that slight. Body armour designed for use in the US coming up short in a crunch testing process and a competitor objection forcing a delay on the delivery of a head protection system for the US army were serious setbacks.

"The body armour issues are now so serious the company has launched a strategic review of this part of the business, signalling it could even be sold off entirely, while its full-year results for the year to 30 September have been delayed and are likely to see significant impairments, even if underlying performance will be in line with expectations.

"Worryingly for management’s credibility, Avon had already updated on its full-year performance in trading update last month, post the period end. For the current financial year, it is a case of wait and see, but it’s hard to be too encouraged."